A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered NEV801 in Subjects With Advanced Malignancies

Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered NEV801 in Subjects With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Camptothecin/podophyllotoxin (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Sponsors Neovia Oncology
  • Most Recent Events

    • 25 Jan 2017 According to a Neovia Oncology media release, this trial will be run by principal investigators at Dana Farber Cancer Institute, Boston; and Sarah Cannon Research Institute, Nashville.
    • 25 Jan 2017 Status changed from not yet recruiting to recruiting, as per a Neovia Oncology media release.
    • 08 Jun 2016 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top